Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

ID#: NCT03859700

Age: 2 - 4 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Enrolling by invitation

Start Date: December 06, 2018

End Date: June 01, 2023

Summary: Open-label, follow-up study for subjects who completed the EPITOPE study.
Eligibility:

Inclusion Criteria:

- completion of the EPITOPE study

Exclusion Criteria:

- Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches.

- Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma